- $594.92m
- $591.86m
- $126.08m
U.S. STOCKS ON THE MOVE- NextDecade, Eli Lilly, Norwegian
Surmodics falls on FDA's response for vascular disease device application
U.S. STOCKS ON THE MOVE-Apple, Surmodics, Domino's
Surmodics falls on FDA's response for vascular disease device application
Brief: Surmodics Provides Update Related To FDA Premarket Approval Application
Brief: Surmodics Announces 12-Month Data From The Swing Trial Presented At VEITHsymposium
Brief: Surmodics Announces Swing Trial 12-Month Data To Be Presented At Veithsymposium On Nov. 16
Surmodics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Surmodics Introduces Fiscal Year 2023 Financial Guidance
Surmodics Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Surmodics Says SurVeil Drug Coated Balloon Demonstrates Sustained Durability Of Safety, Efficacy Endpoints
Brief: Surmodics Announces Transcend Trial 24-Month Data To Be Presented At Viva 2022
Brief: Surmodics Announces New Credit Facilities Providing Up To $125 Mln In Financing
Brief: Surmodics Inc Entered Into Secured Revolving Credit Facility
Surmodics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surmodics Reports Third Quarter Fiscal 2022 Results
Surmodics Inc expected to post a loss of 38 cents a share - Earnings Preview
Surmodics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Surmodics Reports Q2 Fiscal 2022 Results